Log in to save to my catalogue

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1725652713

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

About this item

Full title

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2015-10, Vol.373 (17), p.1627-1639

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In a randomized study involving 582 patients with advanced nonsquamous lung cancer that had progressed after primary treatment, nivolumab produced a higher response rate and longer overall survival than standard docetaxel.
Effective options are limited for patients with nonsquamous non–small-cell lung cancer (NSCLC) whose disease progresses afte...

Alternative Titles

Full title

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1725652713

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1725652713

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1507643

How to access this item